Search PubMed⌕ Search

Biomedical subjects

S Ginsberg

Publications and source records attributed to S Ginsberg.

32 records · Page 2Linked to original sources
PubMed1980

Pharmacokinetics of vinblastine-loaded platelets utilized in the treatment of platelet-phagocytizing tumors.

Vinblastine-loaded platelets (VLP) have been successfully used in the treatment of idiopathic thrombocytopenic purpura. Three patients with platelet-phagocytizing tumors and thrombocytopenia were treated with VLP. Patient 1 has sustained a response for 11 months. Patient 2 was not evaluable for response because of early death. Patient 3 had a brief partial response. Vinblastine levels were measured by radioimmunoassay in the platelet-rich plasma, platelet-poor plasma, and serum. The pharmacokinetic data obtained on the patients suggest that: (a) the amount of vinblastine bound to platelets in vivo is a function of the platelet-poor plasma vinblastine level and the platelet count; (b) VLP will probably not have any therapeutic advantage, compared with iv vinblastine alone in patients with normal platelet counts; and (c) it appears that delivery of vinblastine was tumor-specific, since the bone marrow serum vinblastine level in patient 2, obtained when the marrow was replaced by tumor cells, was 2.5-fold higher than a simultaneous peripheral blood serum vinblastine level after VLP. Additional studies with VLP appear warranted in patients with platelet-phagocytizing tumors resulting in thrombocytopenia.

Adult↗
PubMed1977

Combination chemotherapy and radiotherapy in small-cell carcinoma of the lung.

A combination of chemotherapy (Cytoxan, vincristine, and CCNU) and radiation therapy was used to treat 37 patients with small-cell carcinoma of the lung. There was 49% complete remission and an overall 76% objective response with an overall median survival of 12.5 months and 17 months for those showing a complete response. No serious morbidity was observed.

Carcinoma, Small Cell↗
PubMed1975

Test of an orienting-reaction-recovery account of short-interval autonomic conditioning.

The electrodermal and plethysmographic components of the orienting reaction in 24 subjects were examined in a conditioning-analog arrangement (tones and lights patterned analogously to CS and UCS presentations in classical conditioning) in order to test the orienting-reaction-recovery (ORR) account according to which apparent short-interval autonomic conditioning (SIAC) can be completely accounted for by an ORR effect. The form of the test was to see whether ORR following change from a repeatedly presented forward ('CS-UCS') analog would exceed that to change from a backward ('UCS-CS') analog, as is the case in SIAC with CS-alone test trials following repeated CS-UCS versus UCS-CS pairings. The results did not support the ORR account, although they were shown to be consistent with the relevant experimental literature, when critically examined, and to provide internal evidence for the adequacy of the present test of this particular formulation of the ORR account of SIAC.

Acoustic Stimulation↗
PubMedDate not supplied

Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.

Systemic administration of most chemotherapeutic agents has been assumed to be ineffective in the treatment of primary and metastatic brain tumors because these agents fail to cross the intact blood-brain barrier. However, agents which fail to penetrate the intact blood-brain barrier may penetrate it under conditions which include the presence of tumor in the central nervous system (CNS) and prior CNS irradiation. This paper reports the results of pharmacokinetic studies of bleomycin, cisplatin, and vinblastine in the CNS of a patient with a primary germ cell tumor of the brain who had received prior radiotherapy. Significant concentrations of bleomycin and cisplatin, but not of vinblastine, were reached in the cerebrospinal fluid (CSF) of the patient following iv administration. The area under the bleomycin CSF concentration times time curve was 25% of the area under the bleomycin plasma concentration times time curve. The areas under two cisplatin CSF curves were 50% and 155% of the areas under the corresponding free cisplatin plasma curves. Moreover, an objective response of the tumor to the chemotherapy was documented. This study provides evidence that, under certain circumstances, significant concentrations of cisplatin and bleomycin may be obtained in human CSF following systemic administration and that it may be possible to treat primary or metastatic CNS tumors with agents effective against systemic tumor of the same histologic type.

Antineoplastic Agents↗
PubMedDate not supplied

Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.

Chlorozotocin is a new anticancer agent with the chloroethylnitrosourea cytotoxic moiety attached to the carbon-2 position of glucose. Like other chloroethylnitrosoureas, this agent produces delayed myelotoxicity which is dose-limiting. A phase I trial of chlorozotocin with administration of glucose was done in an attempt to modify the myelotoxicity. The patients received the first course of chlorozotocin (200 mg/m2) in the fasting state and then the second course of chlorozotocin with boluses of a 50% glucose solution. With the second course of chlorozotocin administration, the glucose concentration remained threefold greater than after the first course for at least 1 hour. The plasma half-life and apparent volume of distribution of chlorozotocin were similar following either course. The wbc, neutrophil, and platelet count nadirs after the first course of this agent were not significantly different than the nadirs after the second course. We were unable to modify the myelotoxicity of chlorozotocin with boluses of a 50% glucose solution.

Blood Glucose↗